Insiders Exelixis, Inc.

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
43.96 ^USD	-3.26%		-0.18%	+0.30%

14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
13/01	Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM

Insiders

09/01	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
07/01	Enliven Therapeutics, Inc. Announces Changes in Board, Effective January 7, 2026	CI
25/11	Exelixis Insider Sold Shares Worth $3,046,928, According to a Recent SEC Filing	MT
14/11	Exelixis Insider Sold Shares Worth $4,355,000, According to a Recent SEC Filing	MT
14/11	Exelixis Insider Sold Shares Worth $2,056,278, According to a Recent SEC Filing	MT
14/11	Exelixis Insider Sold Shares Worth $1,032,414, According to a Recent SEC Filing	MT
08/11	Exelixis, Inc. Announces Executive Changes, Effective November 7, 2025	CI
30/25/30	Exelixis announces appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development	RE
30/25/30	Exelixis, Inc. Appoints Dana T. Aftab as Its Executive Vice President, Research and Development	CI
23/25/23	Exelixis Insider Sold Shares Worth $1,515,091, According to a Recent SEC Filing	MT
19/25/19	Exelixis Insider Sold Shares Worth $4,600,000, According to a Recent SEC Filing	MT
19/25/19	Exelixis Insider Sold Shares Worth $1,154,500, According to a Recent SEC Filing	MT
19/25/19	Exelixis Insider Sold Shares Worth $1,619,130, According to a Recent SEC Filing	MT
19/25/19	Exelixis Insider Sold Shares Worth $6,488,503, According to a Recent SEC Filing	MT
19/25/19	Exelixis Insider Sold Shares Worth $3,309,125, According to a Recent SEC Filing	MT
04/25/04	Kalaris Therapeutics, Inc. Appoints Leone Patterson to Its Board of Directors and as Chair of the Board?s Audit Committee	CI
20/25/20	Exelixis Insider Sold Shares Worth $1,541,343, According to a Recent SEC Filing	MT
03/24/03	Exelixis Insider Sold Shares Worth $2,200,200, According to a Recent SEC Filing	MT
20/24/20	Exelixis Insider Sold Shares Worth $1,428,822, According to a Recent SEC Filing	MT
08/24/08	Exelixis Insider Sold Shares Worth $3,394,510, According to a Recent SEC Filing	MT
16/24/16	C4 Therapeutics Names Paige Mahaney as Chief Scientific Officer	MT
26/24/26	Exelixis Insider Sold Shares Worth $659,500, According to a Recent SEC Filing	MT
12/24/12	Exelixis Insider Sold Shares Worth $3,398,750, According to a Recent SEC Filing	MT
12/24/12	Exelixis Insider Sold Shares Worth $2,375,000, According to a Recent SEC Filing	MT
12/24/12	Exelixis Insider Sold Shares Worth $2,077,600, According to a Recent SEC Filing	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Exelixis, Inc. : The cure to cancer?

August 05, 2025 at 07:19 pm IST